leisure time -WSS

leisure time

author：knowledge 2025-09-27 12:49:04 - browse：4

Editor’s note: A recording of the event is embedded below.

Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for?

Let’s dive in and discuss what to watch in the months ahead.

Speakers:

Alex Brill, CEO, Matrix Global Advisors
Chris Brown, managing partner and co-founder, Integrity Rx Partners
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)
Thomas Newcomer, head of U.S. market access, Samsung Bioepis (sponsor speaker)

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Organ aging and disease risk measured by new blood test

focus

WSS

Why a market frenzy over new weight loss drugs defies logic

STAT Summit: The economic case for universal basic health care

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Health tech investors get more selective as pandemic boom fades

STAT Readout Newsletter: Biotech news today

ReNAgade cuts staff seven months after raising $300 million

hotspot

leisure time

focus

Walensky prepares to leave CDC — and Congress — behind

UnitedHealth, Optum discontinue NaviHealth name

Medicare proposal to cover medical devices draws a mixed reaction

The EPA's new lead rule: How one expert crunched the numbers

Walensky prepares to leave CDC — and Congress — behind

Why a market frenzy over new weight loss drugs defies logic

Malaria cases in Florida and Texas: Here’s what you need to know

ReNAgade cuts staff seven months after raising $300 million

Medicare proposal to cover medical devices draws a mixed reaction

STAT Summit: Ending the crisis of Black deaths in the U.S.

focus

Will the market for weight loss drugs really reach $100 billion?

BIO selects John Crowley as new CEO

Roche acquires Telavant from Roivant, adding experimental IBD treatment

With clinical trial data readouts, here's how to spot spin

What don’t we know about an Alzheimer’s drug side effect?

Mayo Clinic plans $5B tech

hotspot

Wikipedia

focus

focus